wepox 4000 injection -
wockhardt limited, india - erythropoietin - injection - -
wosulin-r injection 4 mg/ml
wockhardt limited, india - human insulin - injection - 4 mg/ml
wosulin 30/70 suspension for injection -
wockhardt limited, india - insulin human ep - suspension for injection - -
wosulin n suspension for injection 4mg/ml
wockhardt limited, india - insulin human ep - suspension for injection - 4mg/ml
wosulin r suspension for injection 4mg/ml
wockhardt limited, india - insulin human ep - suspension for injection - 4mg/ml
glaritus solution for injection 100 iu/ml
wockhardt limited, india - insulin glargine - solution for injection - 100 iu/ml
nadoxin cream 10mg/gm
wockhardt limited, india - nadifloxacin - cream - 10mg/gm
nadimix cream 10+20+1 mg
wockhardt limited, india - cream - 10+20+1 mg
nadoxin gel 1 %
wockhardt limited, india - nadifloxacin - gel - 1 %
zonisamide capsule
wockhardt usa llc. - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide 25 mg - zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide capsules are contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonisamide capsules has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.